Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Harrow Inc. (HROW)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 3,905,000 | $191,345,000 | 25.24% | |
| 2. | Private Capital Management Gregg J. Powers | 1,843,091 | $90,311,459 | -1% | 8.28% |
| 3. | Luxor Capital Group Christian Leone | 917,541 | $44,959,509 | +199% | 3.44% |
| 4. | Royce & Associates Chuck Royce | 509,746 | $24,977,554 | -5% | 0.25% |
| 5. | 509,700 | $24,975,300 | +76% | 1.95% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.97 | 20,000 | $199,400.00 | 3,815,000 | 2024-04-25 | Filing | |
| $10.15 | 8,285 | $84,092.75 | 3,795,000 | 2024-04-24 | Filing | |
| $10.29 | 11,715 | $120,547.35 | 3,786,715 | 2024-04-23 | Filing | |
| $10.56 | 29,400 | $310,390.50 | 3,775,000 | 2024-04-19 | Filing | |
| $12.82 | 50,000 | $641,000.00 | 3,745,600 | 2024-03-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $53.35 | 20,000 | $1,066,914.00 | 70,000 | 2026-01-06 | Filing | |
| $30.80 | 15,000 | $462,033.00 | 90,000 | 2025-06-10 | Filing | |
| $30.37 | 15,204 | $461,794.13 | 105,000 | 2025-06-09 | Filing | |
| $30.02 | 1,796 | $53,907.48 | 120,204 | 2025-06-04 | Filing | |
| $30.04 | 3,000 | $90,116.10 | 122,000 | 2025-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,568,402 | $125,851,698 | 0% | |
| 2. | 1,921,683 | $94,162,467 | 0% | |
| 3. | 785,089 | $38,476,665 | 0% | |
| 4. | 783,740 | $38,403,260 | 0% | |
| 5. | 683,500 | $33,491,500 | 0% |
News See All
Harrow Health, Inc. (NASDAQ:HROW) Q3 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Harrow Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on Make Money, Make Time’s Substack by Oliver | MMMT Wealth. In this article, we will summarize the bulls’ thesis on HROW.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on Penny Insight’s Substack. In this article, we will summarize the bulls’ thesis on HROW.
Harrow Health, Inc. (NASDAQ:HROW) Q2 2025 Earnings Call Transcript
Michael D. Biega: Thank you, operator. Good morning, and welcome to Harrow's second quarter 2025 earnings conference call.
Harrow, Inc. (HROW): A Bull Case Theory
We came across a bullish thesis on Harrow, Inc. on 1035 Capital Management’s Substack. In this article, we will summarize the bulls’ thesis on HROW.
William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating
Harrow, Inc. (NASDAQ:HROW) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 10, William Blair analyst Lachlan Hanbury-Brown initiated coverage of Harrow, Inc.
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Hedge Fund Resource Center Billionaire Hedge Funds
